UNITAID to launch patent pool for HIV/AIDS drugs by mid-2010

NewsGuard 100/100 Score
The international drug procurement agency UNITAID on Monday unveiled plans to create a patent pool for HIV/AIDS medications to help increase access to generic versions of newer drugs at lower prices for low- and middle-income countries, Agence France-Presse reports. The patent pool "will create a common space for patent holders to license their technology in exchange for royalties" and is "scheduled to begin operating in mid-2010," AFP reports (12/14).

"UNITAID has committed to provide start-up funds of up to US$ 4 million over the next year," according to a UNITAID press release, which noted an annual savings of more than $1 billion a year is expected through the program. "This is an historic day," said Philippe Douste-Blazy, chair of UNITAID's executive board. "UNITAID has now put in place a mechanism that will make medical advances work for the poor, while compensating companies for sharing their technology" (12/14).

"UNITAID has identified 19 products from nine companies for potential inclusion into the pool," Reuters reports. "The pool will help develop fixed-dose combinations which mix drugs from different companies in a single treatment, it said. Clinical evidence suggests these combinations are the best way for patients to receive safe, effective treatment but patents have created barriers to developing the combinations."

Medecins Sans Frontieres welcomed the move by UNITAID. "'Now that the pool has been given a green light, patent holders need to move from expressions of general support to firm and formal licence commitments,' its policy director, Michelle Childs, said in a statement," according to the news agency (Lynn, 12/15).


Kaiser Health NewsThis article was reprinted from khn.org with permission from the Henry J. Kaiser Family Foundation. Kaiser Health News, an editorially independent news service, is a program of the Kaiser Family Foundation, a nonpartisan health care policy research organization unaffiliated with Kaiser Permanente.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Researchers develop precise drugs to target HIV's Nef protein